Concepts (201)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis C | 8 | 2022 | 1578 | 2.220 |
Why?
|
| Tissue and Organ Procurement | 5 | 2023 | 944 | 1.400 |
Why?
|
| Lung Transplantation | 4 | 2019 | 1304 | 1.320 |
Why?
|
| Heart Transplantation | 5 | 2023 | 3217 | 1.140 |
Why?
|
| Hepatitis C, Chronic | 3 | 2022 | 1031 | 0.980 |
Why?
|
| Hepacivirus | 4 | 2022 | 1333 | 0.950 |
Why?
|
| Organ Transplantation | 4 | 2023 | 1150 | 0.930 |
Why?
|
| Tissue Donors | 13 | 2023 | 2314 | 0.930 |
Why?
|
| Endocarditis | 4 | 2024 | 351 | 0.920 |
Why?
|
| Heart Injuries | 1 | 2021 | 208 | 0.680 |
Why?
|
| Endocarditis, Bacterial | 1 | 2023 | 445 | 0.670 |
Why?
|
| Carbamates | 1 | 2019 | 192 | 0.580 |
Why?
|
| Babesia microti | 1 | 2017 | 31 | 0.560 |
Why?
|
| Babesiosis | 1 | 2017 | 92 | 0.520 |
Why?
|
| Antiviral Agents | 4 | 2022 | 3061 | 0.520 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2017 | 146 | 0.500 |
Why?
|
| Splenectomy | 1 | 2017 | 391 | 0.500 |
Why?
|
| Cardiology | 1 | 2023 | 1723 | 0.410 |
Why?
|
| Fluorodeoxyglucose F18 | 4 | 2024 | 2007 | 0.370 |
Why?
|
| Cardiovascular Infections | 3 | 2024 | 8 | 0.350 |
Why?
|
| Consensus | 4 | 2024 | 3106 | 0.350 |
Why?
|
| Heart-Assist Devices | 1 | 2019 | 1290 | 0.310 |
Why?
|
| Heart Failure | 3 | 2023 | 11835 | 0.310 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 3086 | 0.310 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 3206 | 0.300 |
Why?
|
| Pandemics | 7 | 2022 | 8621 | 0.240 |
Why?
|
| Radiopharmaceuticals | 2 | 2024 | 2633 | 0.230 |
Why?
|
| Antibodies, Neutralizing | 3 | 2021 | 1933 | 0.220 |
Why?
|
| Burkholderia cepacia | 1 | 2022 | 22 | 0.210 |
Why?
|
| Burkholderia cepacia complex | 1 | 2022 | 24 | 0.210 |
Why?
|
| Burkholderia Infections | 1 | 2022 | 41 | 0.210 |
Why?
|
| Antibodies, Viral | 6 | 2023 | 3145 | 0.200 |
Why?
|
| Humans | 45 | 2024 | 760261 | 0.190 |
Why?
|
| RNA, Viral | 2 | 2020 | 2837 | 0.190 |
Why?
|
| Ritonavir | 1 | 2022 | 328 | 0.180 |
Why?
|
| Delphi Technique | 1 | 2024 | 824 | 0.180 |
Why?
|
| Nucleic Acids | 1 | 2023 | 188 | 0.170 |
Why?
|
| Transplants | 1 | 2022 | 206 | 0.170 |
Why?
|
| Neutralization Tests | 1 | 2021 | 729 | 0.170 |
Why?
|
| Health Services Accessibility | 1 | 2017 | 5396 | 0.170 |
Why?
|
| BK Virus | 1 | 2020 | 124 | 0.160 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2020 | 226 | 0.160 |
Why?
|
| Leukocytes | 2 | 2024 | 2030 | 0.160 |
Why?
|
| Hepatitis C Antibodies | 1 | 2019 | 145 | 0.160 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2023 | 642 | 0.160 |
Why?
|
| Fractional Flow Reserve, Myocardial | 1 | 2022 | 329 | 0.160 |
Why?
|
| Paraganglioma | 1 | 2019 | 142 | 0.150 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2018 | 245 | 0.140 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2022 | 572 | 0.140 |
Why?
|
| Troponin T | 1 | 2021 | 774 | 0.140 |
Why?
|
| Heparin | 2 | 2021 | 1655 | 0.140 |
Why?
|
| Viremia | 1 | 2019 | 708 | 0.140 |
Why?
|
| Graft Rejection | 2 | 2020 | 4423 | 0.140 |
Why?
|
| Heart Neoplasms | 1 | 2019 | 360 | 0.130 |
Why?
|
| Pilot Projects | 2 | 2019 | 8553 | 0.130 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2022 | 1724 | 0.130 |
Why?
|
| Standard of Care | 1 | 2019 | 552 | 0.130 |
Why?
|
| Intensive Care Units | 4 | 2022 | 3737 | 0.130 |
Why?
|
| Cross Infection | 1 | 2022 | 1434 | 0.110 |
Why?
|
| Cytomegalovirus | 1 | 2017 | 756 | 0.110 |
Why?
|
| Antigen-Antibody Reactions | 2 | 2021 | 346 | 0.090 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2022 | 1455 | 0.090 |
Why?
|
| Venous Thrombosis | 1 | 2020 | 1293 | 0.090 |
Why?
|
| Cytomegalovirus Infections | 1 | 2017 | 831 | 0.090 |
Why?
|
| Cardiomyopathies | 1 | 2022 | 1945 | 0.090 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2020 | 5644 | 0.090 |
Why?
|
| Heart | 1 | 2023 | 4392 | 0.090 |
Why?
|
| Cost-Benefit Analysis | 1 | 2022 | 5507 | 0.080 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2018 | 1067 | 0.080 |
Why?
|
| Adult | 12 | 2022 | 219847 | 0.080 |
Why?
|
| Sepsis | 1 | 2022 | 2594 | 0.080 |
Why?
|
| Graft Survival | 1 | 2019 | 3793 | 0.080 |
Why?
|
| Thrombosis | 1 | 2022 | 3052 | 0.080 |
Why?
|
| Pyrazoles | 1 | 2018 | 1992 | 0.080 |
Why?
|
| United States | 4 | 2024 | 72363 | 0.080 |
Why?
|
| Autoantibodies | 1 | 2017 | 2119 | 0.080 |
Why?
|
| Decision Trees | 1 | 2020 | 506 | 0.080 |
Why?
|
| B-Lymphocytes | 1 | 2021 | 4739 | 0.070 |
Why?
|
| Predictive Value of Tests | 1 | 2024 | 15273 | 0.070 |
Why?
|
| Immunoglobulin A | 2 | 2021 | 978 | 0.070 |
Why?
|
| Heart Ventricles | 1 | 2019 | 3811 | 0.070 |
Why?
|
| Cohort Studies | 4 | 2022 | 41317 | 0.070 |
Why?
|
| Pulmonary Embolism | 1 | 2020 | 2544 | 0.070 |
Why?
|
| Pyrimidines | 1 | 2018 | 3011 | 0.070 |
Why?
|
| Middle Aged | 9 | 2022 | 220175 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2022 | 64947 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 1 | 2023 | 7400 | 0.060 |
Why?
|
| Hospitalization | 2 | 2022 | 10761 | 0.060 |
Why?
|
| Antineoplastic Agents | 2 | 2018 | 13629 | 0.060 |
Why?
|
| Male | 10 | 2022 | 359413 | 0.060 |
Why?
|
| Prospective Studies | 3 | 2022 | 54263 | 0.050 |
Why?
|
| Nucleocapsid | 1 | 2023 | 63 | 0.050 |
Why?
|
| Coronary Artery Disease | 1 | 2022 | 6661 | 0.050 |
Why?
|
| Community Health Centers | 1 | 2006 | 453 | 0.050 |
Why?
|
| Age Factors | 1 | 2019 | 18415 | 0.050 |
Why?
|
| Female | 12 | 2022 | 391011 | 0.050 |
Why?
|
| Ammonia | 1 | 2022 | 236 | 0.050 |
Why?
|
| Drug Contamination | 1 | 2022 | 152 | 0.050 |
Why?
|
| Blood Donors | 1 | 2023 | 343 | 0.050 |
Why?
|
| Myocardial Infarction | 1 | 2022 | 11891 | 0.050 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2023 | 419 | 0.040 |
Why?
|
| Intubation | 1 | 2020 | 139 | 0.040 |
Why?
|
| Prothrombin Time | 1 | 2020 | 116 | 0.040 |
Why?
|
| Vulnerable Populations | 1 | 2006 | 696 | 0.040 |
Why?
|
| Asymptomatic Infections | 1 | 2021 | 131 | 0.040 |
Why?
|
| Aged | 7 | 2022 | 168995 | 0.040 |
Why?
|
| Respiratory Therapy | 1 | 2020 | 127 | 0.040 |
Why?
|
| Protein Structure, Quaternary | 1 | 2021 | 428 | 0.040 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2021 | 419 | 0.040 |
Why?
|
| Partial Thromboplastin Time | 1 | 2020 | 206 | 0.040 |
Why?
|
| Antigen-Antibody Complex | 1 | 2021 | 513 | 0.040 |
Why?
|
| Immunoglobulin G | 2 | 2021 | 4546 | 0.040 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2020 | 412 | 0.040 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2024 | 1067 | 0.040 |
Why?
|
| Organ Preservation | 1 | 2022 | 379 | 0.040 |
Why?
|
| Prosthesis-Related Infections | 1 | 2024 | 486 | 0.040 |
Why?
|
| Advisory Committees | 1 | 2023 | 789 | 0.040 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 418 | 0.040 |
Why?
|
| Pneumocystis carinii | 1 | 2018 | 72 | 0.040 |
Why?
|
| Immunoassay | 1 | 2021 | 748 | 0.040 |
Why?
|
| Enoxaparin | 1 | 2020 | 397 | 0.040 |
Why?
|
| Urban Population | 1 | 2006 | 2021 | 0.040 |
Why?
|
| Ferritins | 1 | 2020 | 598 | 0.040 |
Why?
|
| American Heart Association | 1 | 2022 | 1081 | 0.040 |
Why?
|
| Carrier State | 1 | 2021 | 525 | 0.040 |
Why?
|
| Cryoelectron Microscopy | 1 | 2021 | 642 | 0.040 |
Why?
|
| Fibrinogen | 1 | 2020 | 887 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 2021 | 1529 | 0.030 |
Why?
|
| Algorithms | 2 | 2024 | 13967 | 0.030 |
Why?
|
| Coronary Circulation | 1 | 2022 | 1578 | 0.030 |
Why?
|
| Sodium | 1 | 2022 | 1601 | 0.030 |
Why?
|
| Crystallography, X-Ray | 1 | 2021 | 1979 | 0.030 |
Why?
|
| Water | 1 | 2022 | 1402 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2022 | 15740 | 0.030 |
Why?
|
| Protein Multimerization | 1 | 2021 | 983 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2021 | 14656 | 0.030 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 621 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2006 | 2689 | 0.030 |
Why?
|
| Mothers | 1 | 2006 | 2186 | 0.030 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 749 | 0.030 |
Why?
|
| Anticoagulants | 2 | 2021 | 4896 | 0.030 |
Why?
|
| Immunity | 1 | 2021 | 998 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2024 | 20484 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2021 | 3804 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2019 | 2120 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2020 | 2646 | 0.030 |
Why?
|
| Age of Onset | 1 | 2021 | 3302 | 0.030 |
Why?
|
| Young Adult | 4 | 2022 | 58673 | 0.030 |
Why?
|
| Propensity Score | 1 | 2021 | 1918 | 0.030 |
Why?
|
| Risk Factors | 2 | 2018 | 74269 | 0.030 |
Why?
|
| Heart Atria | 1 | 2019 | 1344 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 4573 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2021 | 2003 | 0.030 |
Why?
|
| Disease Outbreaks | 1 | 2022 | 1759 | 0.030 |
Why?
|
| Adenine | 1 | 2018 | 976 | 0.030 |
Why?
|
| Incidence | 2 | 2022 | 21378 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 15827 | 0.030 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2017 | 685 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2024 | 3903 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2022 | 5201 | 0.020 |
Why?
|
| Aged, 80 and over | 3 | 2022 | 58947 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2006 | 3967 | 0.020 |
Why?
|
| Piperidines | 1 | 2018 | 1650 | 0.020 |
Why?
|
| Vaccination | 1 | 2022 | 3360 | 0.020 |
Why?
|
| Critical Illness | 1 | 2022 | 2709 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2020 | 3822 | 0.020 |
Why?
|
| Adolescent | 3 | 2022 | 87747 | 0.020 |
Why?
|
| Health Personnel | 1 | 2022 | 3310 | 0.020 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 1539 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2022 | 5420 | 0.020 |
Why?
|
| Boston | 1 | 2020 | 9282 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2020 | 4355 | 0.020 |
Why?
|
| Venous Thromboembolism | 1 | 2020 | 1866 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2020 | 5960 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2020 | 4554 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2020 | 12412 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2022 | 6457 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2022 | 8058 | 0.020 |
Why?
|
| Registries | 1 | 2022 | 8449 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2024 | 20048 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 9388 | 0.020 |
Why?
|
| Lung | 1 | 2023 | 9989 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2021 | 9196 | 0.010 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2019 | 3618 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2021 | 22041 | 0.010 |
Why?
|
| Disease Progression | 1 | 2020 | 13505 | 0.010 |
Why?
|
| Prognosis | 1 | 2024 | 29636 | 0.010 |
Why?
|
| Kenya | 1 | 2006 | 749 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2022 | 80301 | 0.010 |
Why?
|
| Child, Preschool | 2 | 2021 | 42034 | 0.010 |
Why?
|
| Culture | 1 | 2006 | 622 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2021 | 26168 | 0.010 |
Why?
|
| Professional-Patient Relations | 1 | 2006 | 725 | 0.010 |
Why?
|
| Focus Groups | 1 | 2006 | 1372 | 0.010 |
Why?
|
| HIV Infections | 1 | 2006 | 17159 | 0.010 |
Why?
|
| Infant | 1 | 2021 | 36030 | 0.010 |
Why?
|
| Health Care Surveys | 1 | 2006 | 2434 | 0.010 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2006 | 2197 | 0.010 |
Why?
|
| Child | 1 | 2021 | 79758 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2006 | 7803 | 0.010 |
Why?
|
| Anti-HIV Agents | 1 | 2006 | 4492 | 0.010 |
Why?
|
Concepts
(201)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(156)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_